CDK4 and colorectal cancer: Our previous work characterized the metabolic reprogramming associated with CDK4/6 pharmacological inhibition or genetic depletion, uncovering the upregulation of MYC, glutaminolysis, and mTOR signaling as major adaptations of colorectal cancer cells to restore their fitness in response to such perturbations [36].